Document registry — page 26
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
What is the effect of reconstitution practice on the dose actually delivered from a lyophilised research peptide?
Moderate05 Nov 2024 -
Abnormal regional fat distribution with excess visceral adipose tissue, in the setting of HIV infection and antiretroviral therapy.
05 Nov 2024 -
In the population defined for type 2 diabetes mellitus, what is the effect of Lixisenatide compared with the comparator used in its contributing trials on the anchor…
High01 Nov 2024 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 Oct 2024 -
Observational study of Thymalin in immune modulation over not recorded. Primary result: The Institute has not obtained a retrievable protocol or analysis plan and grades…
26 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Oct 2024 -
Consultation on the draft of this methodological review, which registers the question: What is known about the direction and magnitude of the difference between…
18 Oct 2024 -
Difficulty initiating or maintaining sleep with daytime consequences, assessed by polysomnography, actigraphy or validated questionnaires.
18 Oct 2024 -
Consultation on the draft monograph for Larazotide acetate, which the assessment committee released for public comment before ratification. The draft grades the…
16 Oct 2024 -
What is the relationship between the indications in which melanocortin receptor agonists have been evaluated and the uses under which they are supplied?
Low16 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result…
Very low16 Oct 2024 -
Peptides, SARMs, injectable oils and raw materials. Long-established synthesis operation.
15 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low15 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and type 2 diabetes randomising 616 participants over 52 weeks. Primary result…
Moderate14 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Oct 2024 -
In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on heart-failure events?
Moderate11 Oct 2024 -
Consultation on the draft of this network meta-analysis, which registers the question: Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an…
10 Oct 2024 -
Randomised crossover, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2024 -
Consultation on the policy governing how the Institute cites evidence. The draft requires that every citation resolve to a retrievable source, that an identifier the…
05 Oct 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low04 Oct 2024 -
Peptides, SARMs, injectable oils and raw materials.
03 Oct 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low02 Oct 2024 -
Consultation on the draft of this intervention review, which registers the question: What is the effect of an amylin receptor agonist alone and in combination with a…
26 Sep 2024 -
Consultation on the draft monograph for AOD-9604, which the assessment committee released for public comment before ratification. The draft grades the compound's…
25 Sep 2024 -
Peptides, SARMs and raw materials. 350+ catalogue lines.
25 Sep 2024 -
Diagnostic accuracy study of Gonadorelin in gh axis over single test. Primary result: An established diagnostic stimulation test. The Institute records that the…
Moderate22 Sep 2024 -
Record of documents ratified in the 2024 Q3 assessment cycle.
18 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Sep 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in chronic kidney disease and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low12 Sep 2024 -
Single-arm open-label study of Thymalin in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 Sep 2024 -
What can be concluded from a development programme that was discontinued, and how should the Institute record it?
Moderate09 Sep 2024 -
Consultation on the draft monograph for Gonadorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's…
08 Sep 2024 -
Consultation on the policy governing how the Institute corrects a published document and how versions are numbered, retained and linked. The draft retains every…
06 Sep 2024 -
Observational study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low06 Sep 2024 -
Randomised, double-blind, placebo-controlled study of Thymalin in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Sep 2024 -
Consultation on the draft of this analytical evidence review, which registers the question: How large is the discrepancy between labelled peptide mass and delivered…
01 Sep 2024
page 26 of 41